JUL 29, 2020 10:30 AM PDT

Will We Have a COVID-19 Vaccine by Year-End?

WRITTEN BY: Annie Lennon

This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 vaccines. Both say that their vaccines may be available for general use by the end of the year. 

The vaccines are based upon a relatively new practice in which synthetic molecules that mimic the coronavirus are injected into patients instead of the virus itself. In doing so, they teach the immune system to fend off the real thing, while being safe from potential side effects of having it introduced to the body. 

Although faster than traditional production methods and thus easily scalable, as the practice is relatively new, it does not have an extensive track record for efficacy. 

Nevertheless, announcements for the trials come as a part of the US government-funded COVID-19 Prevention Network that plans to roll out studies of leading vaccine candidates every month- each with 30,000 newly recruited volunteers. Aside from seeing if the vaccines work, researchers hope to verify each vaccine's safety profile and then compare results. 

All of this means that large numbers of people will be required to partake in trials, which can often be problematic. Dr. Larry Corey, a virologist who helps oversee the study sites, has said, however, that over 150,000 Americans have already signaled interest in the treatment in online registries. 

While Moderna has received almost $1 billion from the US government to help roll out its vaccine, Pfizer has agreed to sell enough vaccines for 50 million people in the US for around $2 billion should their vaccine work. 

Pfizer has also said that it aims to have around 1.3 billion doses available by the end of 2021- enough to treat 650 million people at two doses each. Meanwhile, Moderna aims to manufacture between 500 million and 1 billion doses per year.

 

Sources: CNBCWashington PostReuters

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 15, 2020
Drug Discovery & Development
FDA Approves HPV Vaccine to Prevent Throat Cancer
JUN 15, 2020
FDA Approves HPV Vaccine to Prevent Throat Cancer
For around a decade, research has suggested that Gardasil, an HPV vaccine, could prevent throat cancer, a condition that ...
JUN 15, 2020
Drug Discovery & Development
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
JUN 15, 2020
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
Researchers from Princeton University have identified a compound capable of killing both Gram-positive and Gram-negative ...
JUN 18, 2020
Drug Discovery & Development
Gilead to Trial COVID-19 Drug on Children
JUN 18, 2020
Gilead to Trial COVID-19 Drug on Children
Following the emergency use authorization given to Remdesivir on May 1, Gilead Sciences has announced that it will condu ...
JUL 15, 2020
Microbiology
A Common Drug Could Help Reduce the Risk of COVID-19 Infections
JUL 15, 2020
A Common Drug Could Help Reduce the Risk of COVID-19 Infections
Heparin is a very common drug that's been approved as an anticoagulant since 1992. Researchers have now found that the m ...
JUL 19, 2020
Cannabis Sciences
Cannabis May Relieve Pain from Sickle Cell Disease
JUL 19, 2020
Cannabis May Relieve Pain from Sickle Cell Disease
Due to the rise in opioid-associated deaths, physicians and researchers are on the constant lookout for new, healthier o ...
AUG 04, 2020
Neuroscience
Transcranial Stimulation Disrupts Fearful Memories
AUG 04, 2020
Transcranial Stimulation Disrupts Fearful Memories
Disrupting negative memory formation has been a challenge for years- involving treatments ranging from psychotherapy to ...
Loading Comments...